☆ 4.6 Article

Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, Research & Experimental

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors

Nicolas Gonzalo Nunez et al.

Summary: In this study, a multi-omics approach was used to characterize the systemic immune compartment of melanoma or non-small cell lung cancer patients before and during immune checkpoint inhibitor (ICI) treatment. Potential predictive biomarkers for ICI-induced immune-related adverse events (irAEs) were identified, including early increase in CXCL9/CXCL10/CXCL11 and interferon-g (IFN-g) 1 to 2 weeks after treatment initiation, as well as early expansion of Ki-67+ regulatory T cells (Tregs) and Ki-67+ CD8+ T cells.

MED (2023)

Add to Collection

Review Oncology

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier

Somayeh Vafaei et al.

Summary: Immune checkpoint inhibitors have become a promising therapeutic strategy with durable anti-tumor effects, but resistance to these inhibitors and treatment-related toxicities pose challenges to their clinical utility. Combination therapy with immune checkpoint inhibitors and other treatments can effectively overcome tumor resistance.

CANCER CELL INTERNATIONAL (2022)

Add to Collection

Article Medicine, General & Internal

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Hussein A. Tawbi et al.

Summary: LAG-3 and PD-1 are two distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab and nivolumab has been shown to be safe and effective in previously treated melanoma patients, and this study aimed to evaluate its safety and activity in previously untreated melanoma patients. The results demonstrated that the combination therapy provided a greater benefit in terms of progression-free survival compared to nivolumab alone, without any new safety signals.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Editorial Material Multidisciplinary Sciences

Immune-related adverse events and the balancing act of immunotherapy COMMENT

Michael Conroy et al.

Summary: The use of immune checkpoint inhibitors comes with immunologic toxicities that affect various organs and have different biology, onset time, and severity.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Immunology

Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy

Vincent T. Ma et al.

Summary: Immune-related adverse events, such as inflammatory arthropathy, are common in cancer patients receiving immunotherapy. This case report highlights the successful treatment of two melanoma patients with immunotherapy-induced inflammatory arthropathy using secukinumab, demonstrating its safety and effectiveness without impacting cancer progression.

IMMUNOTHERAPY (2022)

Add to Collection

Article Oncology

Management of Immunotherapy-Related Toxicities, Version 1.2022

John A. Thompson et al.

Summary: The NCCN Guidelines for Management of Immunotherapy-Related Toxicities aim to provide guidance on managing adverse events resulting from cancer immunotherapy. The guidelines are developed by an interdisciplinary panel of experts from various fields. This article presents excerpts and reviews of recommendations for managing toxicities related to CAR T-cell therapies.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Article Oncology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

J. Haanen et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life

Thomas U. Schulz et al.

Summary: Immune checkpoint inhibitors (ICIs) may induce persistent immune-related adverse events (irAEs) that significantly impact patients' lives. This study revealed that persistent irAEs lead to reduced health-related quality of life (HRQoL), increased burden of autoimmune symptoms, and respective therapies. These findings highlight the importance of careful evaluation of risk-benefit ratios in using ICIs for early-stage tumors and informing patients about potential long-term sequelae.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Clinical advances and ongoing trials of mRNA vaccines for cancer treatment

Cathrine Lund Lorentzen et al.

LANCET ONCOLOGY (2022)

Add to Collection

Article Oncology

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma

Olivier J. van Not et al.

Summary: This cohort study found that second-line immunosuppression for immune-related adverse events (IRAEs) was associated with impaired progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS) in patients with advanced melanoma treated with first-line ipilimumab-nivolumab combination therapy. These findings emphasize the importance of evaluating the effects of different IRAE management strategies.

JAMA ONCOLOGY (2022)

Add to Collection

Article Oncology

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

Anne Montfort et al.

Summary: TNF blockers can help manage gastrointestinal inflammatory side effects following nivolumab and/or ipilimumab treatment in patients with advanced melanoma, and may enhance the efficacy of immune checkpoint inhibitors. The combination of certolizumab showed a high response rate in patients, warranting further investigation. Both combinations were found to be safe and showed clinical and biological activities in human patients.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events

Jia Luo et al.

Summary: The study evaluated the management and outcomes of immune-related adverse events in lung cancer patients treated with immune checkpoint blockade. Results showed that while steroid-refractory or resistant irAEs events are rare, many patients with other irAEs remain refractory or experience toxicities from immunosuppression. Further understanding of the pathophysiology of specific irAEs is needed to guide treatments for severe irAEs effectively.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Letter Medicine, General & Internal

Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors

Anusha S. Thomas et al.

Summary: Two patients developed severe refractory autoimmune colitis after cancer treatment with immune checkpoint inhibitors, but responded well to a course of subcutaneously administered ustekinumab, an antibody that blocks interleukin-12/23 signaling.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Inflammatory markers in autoimmunity induced by checkpoint inhibitors

Beate Husain et al.

Summary: This study found that changes in serum levels of IL-6, CRP, and MIA can be used for early detection of immune-related adverse events (irAE) during treatment with immune checkpoint inhibitors, providing guidance for tailored management.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy

Xue Bai et al.

Summary: A multicenter retrospective analysis found that early high-dose GCC use was associated with poorer survival outcomes in melanoma patients after anti-PD-1 monotherapy, highlighting the need for cautious use of GCC. These findings were validated in a combined validation cohort, confirming the association between high-dose GCC use and worse prognosis.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Review Immunology

Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management

Qin Zhang et al.

Summary: Immunotherapy, specifically PD-1, PD-L1, and CTLA-4 inhibitors, has revolutionized the therapeutic strategy for various malignancies. However, immune-related adverse events such as checkpoint inhibitor pneumonitis (CIP) have become a significant concern, particularly in non-small cell lung cancer patients. The diagnosis and management of CIP in NSCLC patients may be more complicated due to overlapping respiratory symptoms caused by the primary tumor following immunotherapy.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry

Rik J. Verheijden et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Letter Medicine, General & Internal

Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy

Petya Apostolova et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand

James Randall Patrinely et al.

EUROPEAN JOURNAL OF CANCER (2020)

Add to Collection

Article Multidisciplinary Sciences

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Elisabeth Perez-Ruiz et al.

NATURE (2019)

Add to Collection

Article Oncology

IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy

Daniel Johnson et al.

CANCER IMMUNOLOGY RESEARCH (2019)

Add to Collection

Letter Medicine, General & Internal

Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy

Khashayar Esfahani et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Letter Medicine, General & Internal

Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis

Joe-Elie Salem et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Syed S. Mahmood et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

M. R. Migden et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

Dirk Schadendorf et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Howard L. Kaufman et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.